Literature DB >> 7687638

Immortalization of antigen selected B cells.

P G Steenbakkers1, P M van Wezenbeek, W Olijve.   

Abstract

This paper reports the generation of monoclonal antibody producing hybridomas from a small number of antigen-specific B cells selected by panning on antigen-coated dishes and rosetting with antigen-coupled paramagnetic beads. Anti-HIV positive B cells from spleen could be recovered by panning with an efficiency of 5% and a purity of 24%. Immunobead selection of anti-HIV positive B cells from the same mice yielded a recovery of 17% and a purity of 7%. Various experimental conditions with respect to the selection of specific B cells were investigated, leading to an optimized protocol for the isolation of a limited subset of B cells. The selected cells retained their property to produce immunoglobulins and could be clonally expanded in the presence of human T cell supernatant and irradiated murine thymoma helper cells to generate sufficient cells for a mini-electrofusion with NS-1 myeloma cells. Up to 78 specific hybridomas could be generated from one anti-HIV positive B cell. An overall efficiency of specific B cell immortalization of up to 10% was obtained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687638     DOI: 10.1016/0022-1759(93)90236-z

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Development of human monoclonal antibodies: A review.

Authors:  T Lindl
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Efficient generation of monoclonal antibodies from preselected antigen-specific B cells. Efficient immortalization of preselected B cells.

Authors:  P G Steenbakkers; H A Hubers; A W Rijnders
Journal:  Mol Biol Rep       Date:  1994-03       Impact factor: 2.316

3.  An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.

Authors:  Xiaocong Yu; Patricia A McGraw; Frances S House; James E Crowe
Journal:  J Immunol Methods       Date:  2008-05-05       Impact factor: 2.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.